This company has been acquired
REUN Stock Overview
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Reunion Neuroscience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.42 |
| 52 Week High | CA$9.44 |
| 52 Week Low | CA$0.83 |
| Beta | 4.21 |
| 1 Month Change | -2.07% |
| 3 Month Change | 40.59% |
| 1 Year Change | -72.95% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.48% |
Recent News & Updates
Shareholder Returns
| REUN | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -3.4% | 4.0% | -0.8% |
| 1Y | -73.0% | 11.6% | 16.9% |
Return vs Industry: REUN underperformed the Canadian Biotechs industry which returned 21.7% over the past year.
Return vs Market: REUN underperformed the Canadian Market which returned 1.9% over the past year.
Price Volatility
| REUN volatility | |
|---|---|
| REUN Average Weekly Movement | 18.6% |
| Biotechs Industry Average Movement | 12.8% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CA Market | 18.5% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: REUN's share price has been volatile over the past 3 months.
Volatility Over Time: REUN's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 16 | Greg Mayes | reunionneuro.com |
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company’s lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications.
Reunion Neuroscience Inc. Fundamentals Summary
| REUN fundamental statistics | |
|---|---|
| Market cap | CA$16.64m |
| Earnings (TTM) | -CA$38.10m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs REUN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REUN income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$38.10m |
| Earnings | -CA$38.10m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did REUN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/02 03:21 |
| End of Day Share Price | 2023/08/02 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Reunion Neuroscience Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Elemer Piros | D. Boral Capital LLC. |
| Sepehr Manochehry | Eight Capital |